A novel systems pharmacology model for herbal medicine injection: A case using reduning injection

BMC Complementary and Alternative Medicine

Volumn 14, Issue 1, 2014, Pages

  Yang, Haixing ^a,b   Zhang, Wenjuan ^a   Huang, Chao ^a   Zhou, Wei ^a   Yao, Yao ^a   Wang, Zhenzhong ^c,d   Li, Yan ^e   Xiao, Wei ^c,d   Wang, Yonghua ^a  

^a NORTHWEST A F UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

^c JIANGSU KANION PHARMACEUTICAL CO   (China)

^d State Key Laboratory of New tech for Chinese Medicine Pharmaceutical Process   (China)

^e DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

Mechanism of action; Polypharmacology; Reduning injection; Systems pharmacology

Indexed keywords

3, 3', 5 TRIMETHOXY 4',7 EPOXY-8, 5' NEOLIGNAN 4, 9, 9' TRIOL; 3,5 DI O CAFFEOYLQUINIC ACID; 3,5 DI O CAFFEOYLQUINIC METHYL ESTER; 4 O CAFFEOYLQUINIC ACID; 4 O CAFFEOYLQUINIC METHYL ESTER; 4,5 DI O CAFFEOYLQUINIC METHYL ESTER; 5 BENZOFURANCARBOXYLIC ACID; 5 BENZOFURANCARBOXYLIC ACID,2,3 DIHYDRO 2 (4 HYDROXY 3 METHOXYPHENYL) 3 (HYDROXYMETHYL) 7 METHOXY; 5 O CAFFEOYLQUINIC ACID; 5 O CAFFEOYLQUINIC METHYL ESTER; 5H,8H PYRANO[4,3 D]THIAZOLO[3,2 A]PYRIDINE 3 CARBOXYLIC ACID; 6'' O TRANS P COUMAROYLGENIPIN GENTIOBIOSIDE; 6'' O TRANS P FERULOYLGENIPIN GENTIOBIOSIDE; 7 EPI VOGELOSIDE; 7,8,11 TRIHYDROXY 1 HYDROPEROXY 4 GUAIEN 3 ONE; 8 [ALPHA LEVO ARABINOPYRANOSYL (1'' 6') BETA DEXTRO GLUCOPYRANOSYLOXY] 2,6 DIMETHYLCT 2 ENO 1,2'' LACTONE; CHINESE DRUG; GENIPIN 1 BETA DEXTRO GENTIOBIOSIDE; GENIPOSIDE; GENIPOSIDIC ACID; LEVO PHENYLALANINOSECOLOGANIN B; LEVO PHENYLALANINOSECOLOGANIN C; LUTEOLIN; LUTEOLIN 7 GLUCOSIDE; QUERCETIN; RUTOSIDE; SECOXYLOGANIN; THREO 1 (4 HYDROXY 3 METHOXYPHENYL) 2 [2 HYDROXY 4 (3 HYDROXYPROPYL)PHENOXY] 1,3 PROPANEDIOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOGELOSIDE; HERBACEOUS AGENT; PLANT MEDICINAL PRODUCT;

AMBROSIA ANNUAE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHINESE MEDICINE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; GARDENIA JASMINOIDES; HERB; IMMUNE RESPONSE; INFLUENZA; LONICERA JAPONICA; NONHUMAN; ARTEMISIA; BIOLOGICAL MODEL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GARDENIA; HERBAL MEDICINE; HUMAN; INFLUENZA, HUMAN; INJECTION; LONICERA; MACROPHAGE; PHYTOTHERAPY; PROCEDURES;

ARTEMISIA; DRUG DISCOVERY; DRUGS, CHINESE HERBAL; GARDENIA; HERBAL MEDICINE; HUMANS; INFLUENZA, HUMAN; INJECTIONS; LONICERA; MACROPHAGES; MEDICINE, CHINESE TRADITIONAL; MODELS, BIOLOGICAL; PHYTOCHEMICALS; PHYTOTHERAPY;

EID: 84929303689     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-430     Document Type: Article

References (78)

1. Zhou G, Chen S, Wang Z, Chen Z: Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Res 2007,17(4):274-276.
2. Xu H, Wang Y, Liu N: Safety of an injection with a mixture of extracts from Herba Artemisiae annuae, Fructus Gardeniae and Flos Lonicerae. Pharm World Sci 2009,31(4):458-463.
3. Zhang A, Sun H, Wang Z, Sun W, Wang P, Wang X: Metabolomics: towards understanding traditional Chinese medicine. Planta Med 2010,76(17):2026-2035.
4. Quintana-Murci L, Chaix R, Wells RS, Behar DM, Sayar H, Scozzari R, Rengo C, Al-Zahery N, Semino O, Santachiara-Benerecetti AS: Where west meets east: the complex mtDNA landscape of the southwest and central Asian corridor. Am J Hum Genet 2004,74(5):827-845.
5. van der Graaf P, Benson N: Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res 2011,28(7):1460-1464.
6. Zhao S, Iyengar R: Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 2012, 52:505-521.
7. Li P, Chen J, Wang J, Zhou W, Wang X, Li B, Tao W, Wang W, Wang Y, Yang L: Systems pharmacology strategies for drug discovery and combination with applications to CVD. J Ethnopharmacol 2013,151(1):93-107.
8. Tao W, Xu X, Wang X, Li B, Wang Y, Li Y, Yang L: Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol 2012, 145:1-10.
9. Huang C, Zheng C, Li Y, Wang Y, Lu A, Yang L: Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform 2013,15(5):710-733.
10. Li B, Xu X, Wang X, Yu H, Li X, Tao W, Wang Y, Yang L: A systems biology approach to understanding the mechanisms of action of Chinese herbs for treatment of cardiovascular disease. Int J Mol Sci 2012,13(10):13501-13520.
11. Liu H, Wang J, Zhou W, Wang Y, Yang L: Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. J Ethnopharmacol 2013, 52:773-793.
12. Yao Y, Zhang X, Wang Z, Zheng C, Li P, Huang C, Tao W, Xiao W, Wang Y, Huang L: Deciphering the combination principles of traditional Chinese medicine from a systems pharmacology perspective based on Ma-Huang decoction. J Ethnopharmacol 2013,150(2):619-638.
13. Wang X, Xu X, Tao W, Li Y, Wang Y, Yang L: A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease. Evid Based Complement Altern Med 2012., 2012:
14. Li Y, Wang Z, Bi Y, Ding G, Sheng L, Qin J, Xiao W, Li J, Wang Y, Wang X: The evaluation and implementation of direct analysis in real time quadrupole time-of-flight tandem mass spectrometry for characterization and quantification of geniposide in Re Du Ning injections. Rapid Commun Mass Spectrom 2012,26(11):1377-1384.
15. Li H: Study on the Therapeutical Basis of Composite Herbal Medicines of Reduning Injection. 2013. Accepted
16. van de Waterbeemd H, Gifford E: ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2003,2(3):192-204.
17. Tetko I, Tanchuk V, Villa A: Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf Comput Sci 2001,41(5):1407-1421.
18. Lipinski C, Lombardo F, Dominy B, Feeney P: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2012, 46:3-26.
19. Sun H: A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption. J Chem Inf Comput Sci 2004,44(2):748-757.
20. Jorgensen W, Duffy E: Prediction of drug solubility from structure. Adv Drug Deliv Rev 2002,54(3):355-366.
21. Lin J, Yamazaki M: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003,42(1):59-98.
22. Wang Y, Li Y, Yang S, Yang L: Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model 2005,45(3):750-757.
23. Kratochwil N, Huber W, Müller F, Kansy M, Gerber P: Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 2002,64(9):1355-1374.
24. Zsila F, Bikadi Z, Malik D, Hari P, Pechan I, Berces A, Hazai E: Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking. Bioinformatics (Oxford, England) 2011,27(13):1806-1813.
25. Nelson D, Koymans L, Kamataki T, Stegeman J, Feyereisen R, Waxman D, Waterman M, Gotoh O, Coon M, Estabrook R: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996,6(1):1-51.
26. Saunders KC: Automation and robotics in ADME screening. Drug Discov Today Technol 2004,1(4):373-380.
27. Rostkowski M, Spjuth O, Rydberg P: WhichCyp: prediction of cytochromes P450 inhibition. Bioinformatics (Oxford, England) 2013, 29:2051-2052.
28. Manga N, Duffy J, Rowe P, Cronin M: Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res 2005,16(1-2):43-61.
29. Madden JC: In Silico Approaches for Predicting ADME Properties. In Recent Advances in QSAR Studies. Netherlands: Springer; 2010:283-304.
30. Kidron H, Del Amo EM, Vellonen KS, Urtti A: Prediction of the vitreal half-life of small molecular drug-like compounds. Pharm Res 2012,29(12):3302-3311.
31. Boulesteix A-L: PLS dimension reduction for classification with microarray data. Stat Appl Genet Mol Biol 2004,3(1):Article 33.
32. Chung D, Keles S: Sparse partial least squares classification for high dimensional data. Stat Appl Genet Mol Biol 2010,9(1):Article 17.
33. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V: DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. Nucleic Acids Res 2011,39(Database issue):D1035-D1041.
34. Todeschini R, Consonni V: Handbook of Molecular Descriptors. 2008. Wiley.com
35. Walters W, Murcko M: Prediction of 'drug-likeness'. Adv Drug Deliv Rev 2002,54(3):255-271.
36. Ma C, Wang L, Xie X-Q: GPU accelerated chemical similarity calculation for compound library comparison. J Chem Inf Model 2011,51(7):1521-1527.
37. Rix U, Superti-Furga G: Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009,5(9):616-624.
38. Yu H, Chen J, Xu X, Li Y, Zhao H, Fang Y, Li X, Zhou W, Wang W, Wang Y: A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One 2012,7(5):e37608.
39. Keiser M, Roth B, Armbruster B, Ernsberger P, Irwin J, Shoichet B: Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007,25(2):197-206.
40. Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen LJ, Bork P: STITCH 3: zooming in on protein-chemical interactions. Nucleic Acids Res 2012,40(D1):D876-D880.
41. Xu Q, Qu F, Pelkonen O: Network Pharmacology and Traditional Chinese Medicine. 2012.
42. Azuaje FJ, Zhang L, Devaux Y, Wagner DR: Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs. Sci Rep 2011., 1:
43. Li S, Zhang B: Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med 2013,11(2):110-120.
44. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003,13(11):2498-2504.
45. Archetti F, Lanzeni S, Messina E, Vanneschi L: Genetic Programming for Human Oral Bioavailability of Drugs. In Proceedings of the 8th Annual Conference on Genetic and Evolutionary Computation. ACM; 2006:255-262.
46. Di L, Kerns E: Profiling drug-like properties in discovery research. Curr Opin Chem Biol 2003,7(3):402-408.
47. Shang X, Pan H, Li M, Miao X, Ding H: Lonicera japonica Thunb.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol 2011,138(1):1-21.
48. Chen C, Zhou J, Ji C: Quercetin: a potential drug to reverse multidrug resistance. Life Sci 2010,87(11-12):333-338.
49. Lin Y, Shi R, Wang X, Shen H-M: Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr Cancer Drug Targets 2008,8(7):634-646.
50. Rahden-Staron I, Czeczot H, Szumilo M: Induction of rat liver cytochrome P450 isoenzymes CYP 1A and CYP 2B by different fungicides, nitrofurans, and quercetin. Mutat Res 2001,498(1-2):57-66.
51. Choi J, Piao Y, Kang K: Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 2011,34(4):607-613.
52. Ding Y, Zhang T, Tao J, Zhang L, Shi J, Ji G: Potential hepatotoxicity of geniposide, the major iridoid glycoside in dried ripe fruits of Gardenia jasminoides (Zhi-zi). Nat Prod Res 2013, 27:929-933.
53. Tang H, Min G, Ge B, Li Y, Liu X, Jiang S: Evaluation of protective effects of Chi-Zhi-Huang decoction on phase I drug metabolism of liver injured rats by cocktail probe drugs. J Ethnopharmacol 2008,117(3):420-426.
54. Chula S, Hang L, Yinying B, Jianning S, Shi R: The effects of notoginsenoside R (1) on the intestinal absorption of geniposide by the everted rat gut sac model. J Ethnopharmacol 2012,142(1):136-143.
55. Jang G, Harris R, Lau D: Pharmacokinetics and its role in small molecule drug discovery research. Med Res Rev 2001,21(5):382-396.
56. Stoner C, Gifford E, Stankovic C, Lepsy C, Brodfuehrer J, Prasad J, Surendran N: Implementation of an ADME enabling selection and visualization tool for drug discovery. J Pharm Sci 2004,93(5):1131-1141.
57. Boran AD, Iyengar R: Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel 2010,13(3):297-309.
58. Boots A, Haenen G, Bast A: Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008,585(2-3):325-337.
59. Spinella M: The importance of pharmacological synergy in psychoactive herbal medicines. Altern Med Rev 2002,7(2):130-137.
60. Koshikawa N, Hasegawa S, Nagashima Y, Mitsuhashi K, Tsubota Y, Miyata S, Miyagi Y, Yasumitsu H, Miyazaki K: Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol 1998,153937-944(3):937.
61. Taubenberger JK, Morens DM: The pathology of influenza virus infections. Annu Rev Pathol 2008, 3:499-522.
62. Qiucheng L: The present state and prospect of the study of syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi 1998,4(4):242-246.
63. Albert D, Zündorf I, Dingermann T, Müller W, Steinhilber D, Werz O: Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 2002,64(12):1767-1775.
64. McMillan R: Leukotrienes in respiratory disease. Paediatr Respir Rev 2001,2(3):238-244.
65. Wang X, Xu X, Li Y, Li X, Tao W, Li B, Wang Y, Yang L: Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication. Integr Biol (Camb) 2012, 5:351-371.
66. Ehrhardt C, Ludwig S: A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol 2009,11(6):863-871.
67. Fritz J, Ferrero R, Philpott D, Girardin S: Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006,7(12):1250-1257.
68. Chen G, Shaw M, Kim Y, Nuñez G: NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009, 4:365-398.
69. Dinarello C: Biologic basis for interleukin-1 in disease. Blood 1996,87(6):2095-2147.
70. Beg A: Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002,23(11):509-512.
71. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001,2(8):675-680.
72. Fedson D: Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009,3(4):129-142.
73. Pang IK, Iwasaki A: Inflammasomes as mediators of immunity against influenza virus. Trends Immunol 2011,32(1):34-41.
74. Romeo GR, Lee J, Shoelson SE: Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012,32(8):1771-1776.
75. Hsu HY, Wen MH: Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem 2002,277(25):22131-22139.
76. Moncada S: Nitric oxide: discovery and impact on clinical medicine. J R Soc Med 1999,92(4):164-169.
77. Pasparakis M: Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009,9(11):778-788.
78. Mancino A, Lawrence T: Nuclear factor-kappaB and tumor-associated macrophages. Clin Cancer Res 2010,16(3):784-789.